Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$21.17
+2.5%
$23.65
$12.72
$31.77
$2.65B1.581.33 million shs2.71 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$217.38
-1.3%
$173.69
$96.09
$234.29
$11.19B0.59911,931 shs574,229 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.54
-2.0%
$23.81
$11.92
$27.72
$11.81B1.695.14 million shs8.29 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.25
-1.3%
$13.72
$12.77
$16.17
$11.04B0.272.65 million shs2.54 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
+2.47%-9.34%-13.84%-22.51%+55.15%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.11%+5.25%+21.51%+19.08%+96.09%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.20%+4.41%+0.29%-6.79%+95.31%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-1.45%-3.46%-0.26%-5.89%-1.92%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$21.17
+2.5%
$23.65
$12.72
$31.77
$2.65B1.581.33 million shs2.71 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$217.38
-1.3%
$173.69
$96.09
$234.29
$11.19B0.59911,931 shs574,229 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.54
-2.0%
$23.81
$11.92
$27.72
$11.81B1.695.14 million shs8.29 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.25
-1.3%
$13.72
$12.77
$16.17
$11.04B0.272.65 million shs2.54 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
+2.47%-9.34%-13.84%-22.51%+55.15%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.11%+5.25%+21.51%+19.08%+96.09%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.20%+4.41%+0.29%-6.79%+95.31%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-1.45%-3.46%-0.26%-5.89%-1.92%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.50
Moderate Buy$34.0060.60% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.90
Moderate Buy$251.2615.59% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.2019.82% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$16.9027.55% Upside

Current Analyst Ratings Breakdown

Latest ARQT, AXSM, ELAN, and RDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Reiterated RatingBuy$36.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetOverweight$28.00 ➝ $30.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$242.00 ➝ $302.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$270.00 ➝ $290.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetEqual Weight$217.00 ➝ $242.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOverweight$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$228.00 ➝ $310.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$241.00 ➝ $246.00
(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$376.07M7.04N/AN/A$1.52 per share13.93
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M17.52N/AN/A$1.06 per share205.08
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.49$2.31 per share10.19$13.01 per share1.81
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B2.90$1.03 per share12.81$4.73 per share2.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$16.14M-$0.03N/A22.28N/A-0.57%-1.41%-0.59%N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A53.94N/A-26.59%-267.16%-28.53%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.942.68-4.95%7.42%3.66%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.7717.2122.8420.5516.41%15.89%10.73%5/12/2026 (Estimated)

Latest ARQT, AXSM, ELAN, and RDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09N/AN/AN/A$886.58 millionN/A
5/6/2026Q1 2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
2/25/2026Q4 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$0.03$0.13+$0.10$999.00$110.79 million$129.50 million
2/24/2026Q4 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.11$0.13+$0.02-$0.56$1.09 billion$1.14 billion
2/23/2026Q4 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.53%+9.86%9.09%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.54
2.68
2.99
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.08
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.88
1.38

Institutional Ownership

CompanyInstitutional Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150125.08 million113.33 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.65 million817.96 millionOptionable

Recent News About These Companies

Doctor Reddy's: Fiscal Q3 Earnings Snapshot
Dr. Reddy's Laboratories Ltd (RDY) Stock Forecasts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$21.17 +0.51 (+2.47%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$21.08 -0.10 (-0.45%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$217.38 -2.84 (-1.29%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$217.62 +0.25 (+0.11%)
As of 05/8/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$23.54 -0.48 (-1.98%)
Closing price 05/8/2026 03:58 PM Eastern
Extended Trading
$23.30 -0.23 (-0.98%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$13.25 -0.18 (-1.34%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$13.22 -0.03 (-0.23%)
As of 05/8/2026 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.